Overdose Deaths Are Plummeting—Here's What's Actually Working

Overdose deaths in the United States are falling at the fastest pace in decades, with Centers for Disease Control projections showing a nearly 25% decline for the twelve months ending in April 2025. This dramatic turnaround represents more than statistics—it means families have empty chairs filled at holiday tables and loved ones making it home from work each day.

What's Behind This Historic Decline?

The drop didn't happen by accident. It's the result of specific policy changes that finally aligned with evidence-based treatment approaches. Policymakers expanded access to medications for opioid use disorder, protected telehealth services for addiction treatment, and made naloxone more widely available in communities.

The most significant breakthrough has been improving access to medications like buprenorphine and methadone, which cut the risk of death by more than half. For years, federal rules and insurance barriers kept these life-saving treatments out of reach, but recent changes have started closing these gaps.

Could Weight Loss Drugs Help Fight Addiction Too?

Meanwhile, researchers are exploring an unexpected ally in the fight against addiction: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), the same medications used for diabetes and weight loss. These drugs, which include semaglutide and exenatide, appear to modulate brain pathways involved in addictive behaviors.

"Early research in both animals and humans suggests that these treatments may help reduce alcohol and other substance use," said lead researcher Lorenzo Leggio, M.D., Ph.D., of the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism.

Studies examining GLP-1 effects on substance use disorders have shown promising results across multiple addiction types:

• Alcohol Use Disorder: A recent randomized controlled trial found that low-dose semaglutide reduced laboratory alcohol self-administration, drinks per drinking days, and craving in people with alcohol use disorder
• Opioid Use Disorder: In rodent studies, several GLP-1 receptor agonists reduced self-administration of heroin, fentanyl, and oxycodone, while also reducing drug-seeking behavior that models relapse
• Tobacco Use Disorder: Preclinical data show these medications reduce nicotine self-administration and other nicotine-related outcomes in rodents, with initial clinical trials suggesting potential to reduce cigarettes per day

Why This Progress Could Disappear in 2026

Despite the encouraging trends, the policies driving this success remain vulnerable. Telehealth flexibilities that have become "one of the most powerful drivers of improved access" will vanish unless Congress acts in 2026. Research shows patients who begin treatment virtually stay in recovery at similar or higher rates than those who start in person.

Insurance coverage changes pose another threat. Medicaid covers nearly half of non-elderly adults with opioid use disorder, but during the unwinding of pandemic protections, more than 23 million people have already lost Medicaid coverage, often due to paperwork errors rather than actual changes in eligibility.

The Congressional Budget Office warns that proposed legislation could slash Medicaid and Children's Health Insurance Program spending by nearly $1 trillion over a decade, potentially eliminating over 10 million people from these programs. Additionally, about 1.5 million Americans could become uninsured in 2026 if Congress delays extending enhanced tax credits under the Affordable Care Act.

"The difference between momentum and reversal now runs through the legislative decisions that will shape 2026," the analysis notes. While current treatments for substance use disorders fall short of addressing public health needs, with less than a quarter of people receiving treatment in 2023, the recent progress shows what's possible when evidence-based approaches receive proper support.